dr. shaw on alectinib as first-line therapy in lung cancer
Published 7 years ago • 1.6K plays • Length 2:26Download video MP4
Download video MP3
Similar videos
-
6:51
progression in alk nsclc after frontline therapy
-
1:58
dr. shaw on crizotinib in alk-positive lung cancer
-
1:35
dr. shaw on the phase iii results of the alex trial in nsclc
-
1:57
dr. shaw on sequencing strategies in alk-positive nsclc
-
1:45
dr. shaw on using crizotinib to treat lung cancer
-
1:51
dr. shaw on ldk378 in alk crizotinib-resistant nsclc patients
-
3:59
alectinib in alk-mutated nsclc
-
2:32
dr. shaw discusses ldk378 and alectinib (af802) for alk-positive nsclc
-
2:06
dr. alice t. shaw on ceritinib for frontline alk nsclc with brain metastases
-
1:07
dr. massarelli on first-line alk nsclc treatment
-
5:52
ceritinib and alectinib in relapsed alk nsclc
-
1:42
dr. alice shaw compares crizotinib and chemotherapy in nsclc
-
6:41
next-generation alk inhibitors for nsclc
-
1:21
dr. shaw on crizotinib resistance in alk-positive lung cancer
-
4:00
alectinib eclipses crizotnib for alk positive lung cancer
-
1:52
dr. shaw on crizotinib versus chemotherapy in alk-positive nsclc
-
3:04
phase iii results for alectinib compared with crizotinib in alk metastatic nsclc
-
7:13
alectinib for relapsed/refractory alk nsclc
-
0:55
dr. west on fda approval of frontline alectinib in alk nsclc